National heart, lung, and blood institute strategic visioning: Setting an agenda together for the NHLBI of 2025

American Journal of Public Health

Volumn 105, Issue 5, 2015, Pages e25-e28

  Mensah, George A ^a   Kiley, James ^a   Mockrin, Stephen C ^a   Lauer, Michael ^a   Hoots, W Keith ^a   Patel, Yasin ^a   Cook, Nakela L ^a   Patterson, Amy P ^a   Gibbons, Gary H ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTITUDE TO HEALTH; HEALTH PROMOTION; HUMAN; LEADERSHIP; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; ORGANIZATION; ORGANIZATION AND MANAGEMENT; UNITED STATES;

BIOMEDICAL RESEARCH; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HUMANS; LEADERSHIP; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); ORGANIZATIONAL OBJECTIVES; UNITED STATES;

EID: 84926642457     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302605     Document Type: Review

References (15)

1. Mahmood S, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999-1008.
2. Nair P. Brown and Goldstein: the cholesterol chronicles. Proc Natl Acad Sci U S A. 2013;110(37):14829-14832.
3. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1968-1978. CDC WONDER Online Database, compiled from Compressed Mortality File CMF 1968-1988, Series 20, No. 2A, 2000. Available at: http://wonder.cdc.gov/cmf-icd8.html. Accessed January 12, 2015.
4. Deaths: final data for 2013. Table 16. Natl Vital Stat Rep. 2014;64(2):1-71. Available at: http://www.cdc.gov/nchs/products/nvsr.htm. Accessed February 4, 2015.
5. Crosby J, Peloso GM, Auer PL, et al.; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014 Jul. 3; 371(1):22-31.
6. Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun. 2014;5:3065.
7. Galbán CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012;18(11):1711-1715.
8. Castaldi PJ, Dy J, Ross J, et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax. 2014;69(5):415-422.
9. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
10. US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591-608.
11. National Center for Health Statistics. Health, United States, 2013: With Special Feature on Prescription Drugs. CDC, NCHS. Available at: http://www.cdc.gov/nchs/data/hus/hus13.pdf. Accessed January 12, 2015.
12. US Department of Health and Human Services. 2013 National Healthcare Disparities Report. Agency for Healthcare Research and Quality: Rockville, MD. Available at: http://www.ahrq.gov/research/findings/nhqrdr/nhqr13/2013nhqr.pdf. Accessed January 12, 2015.
13. Collins FS. Research agenda. Opportunities for research and NIH. Science. 2010;327(5961):36-37.
14. National Heart, Lung, and Blood Institute. NHLBI Strategic Plan. National Institutes of Health, 2007. Available at: http://www.nhlbi.nih.gov/about/strategicplan/index.htm. Accessed January 12, 2015.
15. National Heart, Lung, and Blood Institute. Strategic Visioning: Charting our Future Together. Available at: http://strategicvisioning.nhlbi.nih.gov [registration required]. Accessed February 4, 2015.